The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors

被引:13
作者
Shen, Xianjuan [1 ]
Wang, Mei [2 ]
Guo, Yuehua [2 ]
Ju, Shaoqing [1 ]
机构
[1] Nantong Univ, Affiliated Hosp, Surg Comprehens Lab, Nantong, Peoples R China
[2] Nantong Univ, Med Off, Nantong, Peoples R China
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2016年 / 25卷 / 05期
关键词
BAFF; RFQ-PCR; NHL; BAFF; STIMULATOR; BLYS;
D O I
10.17219/acem/29182
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Lymphoma is a malignant tumor of the immune system originating from lymph nodes and extra-lymphatic tissues. Its occurrence is believed to be associated with various immune cells due to the proliferation and differentiation of lymphocytes during the immune response. It has been found in many studies that B-cell activating factor (BAFF), as a member of the tumor necrosis factor (TNF) superfamily, could specifically activate B lymphocytes and promote their proliferation. Objectives. To explore correlations between non-Hodgkin lymphoma (NHL) and the expression of BAFF and its receptors in NHL patients. Material and Methods. The protein expression of BAFF and its receptors in serum and BAFF mRNA expression in peripheral blood mononuclear cells (PBMCs) of 47 NHL patients and 20 healthy subjects were detected by ELISA and RFQ-PCR and compared with LDH and beta(2) M levels. Results. BAFF mRNA expression in the PBMCs of NHL patients was significantly higher than in healthy controls. The expression levels of serum BAFF and the three receptors (TACI, BCMA and BAFF-R) in NHL patients were significantly higher than in healthy controls, and were not significantly correlated with beta(2) M and LDH levels. Conclusions. The serum protein concentration of BAFF and the expression level of BAFF mRNA in PBMCs of NHL patients underwent abnormal changes, indicating that BAFF and its receptors may play some role in the pathogenesis of NHL
引用
收藏
页码:837 / 844
页数:8
相关论文
共 50 条
[31]   Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma [J].
Rong Shi ;
Tong Lu ;
Grace Ku ;
Hao Ding ;
Tomohisa Saito ;
Leonid Gibiansky ;
Priya Agarwal ;
Xiaobin Li ;
Jin Yan Jin ;
Sandhya Girish ;
Dale Miles ;
Chunze Li ;
Dan Lu .
Cancer Chemotherapy and Pharmacology, 2020, 86 :347-359
[32]   Combined Therapy with Rituximab Plus Cyclophosphamide/Vincristine/Prednisone for Sjogren’s Syndrome-Associated B-Cell Non-Hodgkin’s Lymphoma [J].
J. Carbone ;
R. Perez-Fernandez ;
A. Muñoz ;
P. Sabin ;
L. Carreño ;
E. Fernandez-Cruz .
Clinical Reviews in Allergy & Immunology, 2008, 34 :80-84
[33]   Primary B Cell Non-Hodgkin's Lymphoma Presenting With Multiple Osteolytic Bony Lesions In Skull [J].
Patil, Maya ;
Pratinidhi, Shilpa Aditya ;
Malik, Ajay ;
Gulati, Rachana ;
Joshi, Avinash R. .
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2011, 5 (07) :1464-1466
[34]   Serum B-cell activating factor predicts prognosis in nasal type, extranodal NK/T cell lymphoma [J].
Zhang, Li ;
Li, Na ;
Yang, Li ;
Zhang, Jing ;
Weng, Hua-wei ;
Zou, Li-qun .
CYTOKINE, 2016, 88 :196-198
[35]   Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin's lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma [J].
Byford, Elliot T. ;
Carr, Matthew ;
Ladikou, Eleni ;
Ahearne, Matthew J. ;
Wagner, Simon D. .
PLOS ONE, 2018, 13 (01)
[36]   Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia [J].
Frost, Eleanor ;
Hofmann, Jonathan N. ;
Huang, Wen-Yi ;
Frazer-Abel, Ashley A. ;
Deane, Kevin D. ;
Berndt, Sonja I. .
BLOOD CANCER JOURNAL, 2024, 14 (01)
[37]   Short Report: Elevation of Serum B-Cell Activating Factor Levels During Visceral Leishmaniasis [J].
Goto, Yasuyuki ;
Omachi, Satoko ;
Sanjoba, Chizu ;
Matsumoto, Yoshitsugu .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2014, 91 (05) :912-914
[38]   Correlation Between B-Cell Activating Factor of the Tumor Necrosis Factor Family Level in Serum and Immune Inflammation in Patients with Neuropsychiatric Systemic Lupus Erythematosus and its Clinical Value [J].
Pang, Jie ;
Li, Yanxia ;
Tao, Ran ;
Li, Jing ;
Wang, Feifei ;
Xu, Huaheng .
IMMUNOLOGICAL INVESTIGATIONS, 2024, 53 (04) :559-573
[39]   Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma [J].
Jurczak, W. ;
Zinzani, P. L. ;
Gaidano, G. ;
Goy, A. ;
Provencio, M. ;
Nagy, Z. ;
Robak, T. ;
Maddocks, K. ;
Buske, C. ;
Ambarkhane, S. ;
Winderlich, M. ;
Dirnberger-Hertweck, M. ;
Korolkiewicz, R. ;
Blum, K. A. .
ANNALS OF ONCOLOGY, 2018, 29 (05) :1266-1272
[40]   Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell Non-Hodgkin Lymphoma (iNHL) [J].
Dreyling, M. H. ;
Viardot, A. ;
Salles, G. ;
Wagner-Johnston, N. D. ;
Kahl, B. S. ;
De Vos, S. ;
Schuster, S. J. ;
Jurczak, W. ;
Flinn, I. W. ;
Flowers, C. ;
Martin, P. ;
Blum, K. A. ;
Davies, A. J. ;
Zinzani, P. L. ;
Wagner, L., I ;
Gopal, A. K. ;
Ruppert, S. ;
Kroenig, H. ;
Schuster, A. .
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 :185-185